Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Leukemia, Myeloid, Chronic-Phase (CML-CP)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT05311943
What this trial is testing

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Who this might be right for
OlverembatinibChronic Myeloid Leukemia, Chronic PhaseTyrosine Kinase Inhibitors
Shenzhen Second People's Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01784068
What this trial is testing

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 215
Large-scale testing (Phase 3)Study completedNCT02272777
What this trial is testing

Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Who this might be right for
Leukemia
Novartis Pharmaceuticals 225
Large-scale testing (Phase 3)Ended earlyNCT00519090
What this trial is testing

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Myelogenous Leukemia
Novartis Pharmaceuticals 6
Post-approval studies (Phase 4)UnknownNCT04677439
What this trial is testing

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Who this might be right for
FlumatinibChronic Myeloid Leukemia, Chronic PhaseImatinib
Shenzhen Second People's Hospital 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03817398
What this trial is testing

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Children's Oncology Group 110
Post-approval studies (Phase 4)UnknownNCT04933526
What this trial is testing

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Who this might be right for
Chronic Myeloid Leukemia in Chronic Phase
Shenzhen Second People's Hospital 118
Testing effectiveness (Phase 2)Study completedNCT02467270
What this trial is testing

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Who this might be right for
Myeloid Leukemia, Chronic, Chronic Phase
Takeda 283
Not applicableAvailableNCT04360005
What this trial is testing

Managed Access Programs for ABL001, Asciminib

Who this might be right for
Chronic Myeloid Leukemia in Chronic Phase
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT01077544
What this trial is testing

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
Novartis Pharmaceuticals 15
Post-approval studies (Phase 4)Looking for participantsNCT04877522
What this trial is testing

Asciminib Roll-over Study

Who this might be right for
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals 347
Large-scale testing (Phase 3)Study completedNCT00333840
What this trial is testing

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 1,106
Testing effectiveness (Phase 2)Study completedNCT01216085
What this trial is testing

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

Who this might be right for
CMLImatinib
Novartis Pharmaceuticals 10
Post-approval studies (Phase 4)Ended earlyNCT01131325
What this trial is testing

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

Who this might be right for
CMLPhiladelphia Chromosome Positive (Ph+)Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Novartis Pharmaceuticals 3
Not applicableUnknownNCT04739826
What this trial is testing

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Who this might be right for
CML, Chronic Phase; TKI
The First Affiliated Hospital of Soochow University 491
Large-scale testing (Phase 3)Ended earlyNCT00124748
What this trial is testing

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Who this might be right for
Leukemia, Myeloid, Chronic Phase
Novartis Pharmaceuticals 476
Testing effectiveness (Phase 2)Study completedNCT01856283
What this trial is testing

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Who this might be right for
Leukemia, Myeloid, Chronic-Phase
Niguarda Hospital 87
Not applicableStudy completedNCT03509896
What this trial is testing

Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Chronic Myeloid LeukemiaPhiladelphia ChromosomeChronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb 463
Testing effectiveness (Phase 2)Study completedNCT03578367
What this trial is testing

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Who this might be right for
CMLChronic Myelogenous LeukemiaLeukemia, Myeloid Chronic+1 more
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)Looking for participantsNCT07354074
What this trial is testing

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Who this might be right for
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals 50
Next Page